

CIN: L24110TG1989PLC009497

To, Date: February 4, 2025

The Manager
BSE Limited
P. J. Towers, Dalal Street
Mumbai-400001
(BSE Scrip Code: 543389)

The Manager,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai- 400051.
(NSE Symbol: SIGACHI)

Dear Sir/Madam,

Sub: Press Release- To enhance Research and Development (R&D) capabilities, Sigachi is establishing a state-of-the-art R&D Center in Hyderabad, bringing its critical API developments and Analytical Efforts under one roof

Sigachi Industries Limited, a leading player in pharmaceutical industry is pleased to announce regarding its efficient resource deployment and enhancing R&D Productivity by establishing Research and Development facility in Hyderabad, India. This strategic initiative involves an investment of up to USD 1 Million and is set to commence immediately, reinforcing Sigachi's commitment to innovation and long-term growth and efficiency.

A press release to this extent is enclosed for your information and records.

Thanking you.

Yours Faithfully,
For Sigachi Industries Limited

Vivek Kumar Company Secretary & Compliance Officer



Registered Office



CIN: L24110TG1989PLC009497

To enhance Research and Development (R&D) capabilities, Sigachi is establishing a state-of-the-art R&D Center in Hyderabad, bringing its critical API developments and Analytical Efforts under one roof. This initiative underscores the company's commitment to innovation, operational efficiency, and advancing pharmaceutical solutions.

Tuesday, 4th February 2025: Sigachi Industries Limited, a leading player in Pharmaceutical Industry provided an update regarding its efficient resource deployment and enhancing R&D Productivity by establishing Research and Development facility in Hyderabad, India. This strategic initiative involves an investment of up to USD 1 Million and is set to commence immediately, reinforcing Sigachi's commitment to innovation and long-term growth and efficiency

Strengthening the Pipeline through Increased R&D Investment

Sigachi is committed to revolutionizing API development by advancing synthesis and analytical processes that enhance quality and impact lives. To achieve this, the company is intensifying its R&D investments to drive high-value innovation and looking to fuel additional 6 CEP's in coming 6 months. These strategic investments will not only support the development of existing and new molecules but also reinforce Sigachi's long-term growth trajectory, ensuring sustained profitability and market leadership

The new facility is designed to:

- Optimize API production by integrating advanced systems and adhering to stringent global regulatory standards, ensuring high-quality outputs that meet international benchmarks.
- Drive sustainable growth by expanding the company's development pipeline and accelerating R&D progress with a dedicated investment of up to USD 1 Million.
- Nurture talent by employing a team of 15-20 skilled R&D scientists dedicated to accelerating product development for regulated markets.
- Streamlining Pharma Product Portfolio to focus on priority API's and Intermediates
- Allowing synergies for manufacturing cutting edge API's and regulatory filings under the same roof



Registered Office



CIN: L24110TG1989PLC009497

Commenting on this development, Amit Raj Sinha, Managing Director and CEO of Sigachi Industries Limited stated

"We have made significant progress by delivering Active Pharmaceutical Ingredients (APIs) to the pharmaceutical market. Our increased commitment to R&D is a clear testament to our strategic vision for innovation and excellence. By deepening our investments in R&D, we are not only accelerating our development efforts but also reinforcing our long-term growth objectives and strengthening Sigachi's overall pipeline."

For further information on the Company, please visit www.sigachi.com

About Sigachi Industries Ltd

About Sigachi: Advancing Innovation in Pharmaceutical Ingredients

Sigachi Industries Limited is a global player in the pharmaceutical industry, dedicated to pioneering advancements in Active Pharmaceutical Ingredients (APIs), Intermediates, Excipients, Vitamin Mineral Nutrient Blends and O&M services. With a strong focus on innovation, quality, and regulatory compliance, we leverage cutting-edge technology and global expertise to develop high-value pharmaceutical solutions that enhance healthcare outcomes. Committed to excellence, we continuously invest in Research and Development, ensuring the highest standards of quality and safety. With over 35 years of industry experience, Sigachi has emerged as a trusted partner for pharmaceutical and nutraceutical companies spread across 65+ countries. The company's diverse product portfolio is manufactured in 5 multilocational facilities present in Telangana, Gujarat and Karnataka and has its subsidiaries in MEA & US. At Sigachi, we collaborate with healthcare partners, regulatory bodies, and global stakeholders to expand access to reliable, high-quality pharmaceutical ingredients.

For further information, please contact:

Mr. Chaitanya Rapol

Senior Manager – Marketing, Branding and Communications

Sigachi Industries Limited

Email: Chaitanya.rapol@sigachi.com



Registered Office



CIN: L24110TG1989PLC009497

Forward-Looking Statements

This press release contains forward-looking statements that reflect the current expectations and projections of Sigachi Industries Limited regarding future business performance, research and development initiatives, and strategic growth plans. These statements, which include but are not limited to anticipated investments, R&D advancements, regulatory developments, and commercial potential of new and existing molecules, are based on management's beliefs, assumptions, and estimates as of the date of this release.

Forward-looking statements are generally identified by terms such as "aims," "expects," "intends," "plans," "believes," "seeks," "estimates," "potential," "future," and similar expressions. However, actual results may differ materially from those projected due to various risks and uncertainties, including but not limited to regulatory approvals, market conditions, research outcomes, operational challenges, and broader economic factors.

Sigachi Industries Limited undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable laws.



Registered Office